마스트바이오

비상장계속사업자

MastBio Co., Ltd.

이창우

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

마스트바이오

Business Reg. No. 2148745932 · CEO 이창우

I.Investment Overview

Target마스트바이오 (2148745932)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명마스트바이오
영문명MastBio Co., Ltd.
대표자이창우
사업자등록번호2148745932
법인등록번호1101112921602
설립일2003.12.24

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW73.3202196.22022113.22023109.22024148.32025
영업이익100M KRW17.2202111.3202213.220239.420246.32025
순이익100M KRW14.52021420229.220235.620245.82025
Item20252024202320222021
자산총계237.6억원192.6억원189.7억원189.4억원164.8억원
부채총계143.6억원104.5억원107.2억원115.9억원94.7억원
자본총계93.9억원88.1억원82.5억원73.5억원70.1억원
매출액148.3억원109.2억원113.2억원96.2억원73.3억원
영업이익6.3억원9.4억원13.2억원11.3억원17.2억원
순이익5.8억원5.6억원9.2억원4억원14.5억원

VI.Financial Ratios

FY2025 basis

4.22%

영업이익률

3.93%

순이익률

2.46%

ROA

6.21%

ROE

152.92%

부채비율

39.54%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

마스트바이오 투심보고서 | Alpha Lenz